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Abstract 
Relative mean telomere sequence amount was determined by quantitative PCR (qPCR) of peripheral blood 
leukocyte (PBL) samples obtained at recruitment (n = 310) from individuals from the Osteoarthritis (OA) 
Initiative consortium. Knees were radiologically evaluated according to the Kellgren–Lawrence (KL) score, 
ranging from 0 to 4, considering a KL grade ≥ 2 as radiographic evidence of OA (n = 124). Telomere size 
decreased as baseline KL score increased, being significantly shorter in subjects with KL ≥2 (Mann–Whitney 
U‐test, P < 0.0001). PBL telomere size was also associated with age, hypertension, body mass index (BMI) 
and waist circumference. Nevertheless, logistic regression analysis showed that PBL telomere size was a 
consistent risk factor for concurrent knee OA, independent of these health parameters. Shorter PBL telomeres 
may indicate a premature aging status which enhances chondrocyte senescence and degenerative joint 
disease. 









Telomeres are nucleoprotein structures assembled at the ends of eukaryotic chromosomes. 
They perform a capping function protecting chromosomes from recognition as damaged DNA 
ends and inappropriate degradation, therefore being essential to genome integrity and stability 
(Lansdorp, 2009). DNA of human telomeres comprises near 5–15 kb of a tandem repeated G‐rich 
sequence (5′‐TTAGGG‐3′) paired with a C‐rich complementary strand (5'‐CCCTAA‐3′). Protein 
complexes organize with telomeric DNA contributing to structural stability and regulating 
telomere length. These include the shelterin complexes and nucleosomes enriched in epigenetic 
modifications, which contribute to a compacted chromatin packing. Moreover, TERRA 
(Telomere‐Repeat‐Containing‐RNA) is a long noncoding RNA which participates in the 
organization of the telomeric chromatin structure and telomere capping (Galati et al., 2013).  
 
Telomere biology is strongly associated with aging and age‐related pathologies. After each 
round of DNA replication there is a loss of 50–150 pb of the end of the telomere sequence. 
Telomerase replaces the telomeric sequences, but somatic cells do not show telomerase activity so 
telomeres progressively shorten with aging. When critically eroded, telomeres lose their capping 
function and trigger a DNA damage response resulting in replicative senescence, where cells stop 
dividing or die through apoptosis. The replicative senescence is a tumor suppressor mechanism to 
avoid the chromosomal instability which would result from end‐to‐end chromosomal fusions by 
uncapped telomeres (Lansdorp, 2009).  
 
Telomere length decreases with aging in somatic cells and could be a factual marker of 
biological age. Accordingly, several studies in human populations point to telomere size measured 
in peripheral blood leukocytes (PBL) as a predictor of lifespan (Deelen et al., 2014; Rode et al., 
2015). Moreover, several meta‐analyses suggest that telomere size measured in PBL is useful to 
assess the individual predisposition to numerous pathologies associated to aging, like several 
cancers, diabetes and cardiovascular disease (Ma et al., 2011; Zhao et al., 2013; Haycock et al., 
2014).  
 
Osteoarthritis (OA) is an age‐related chronic disease characterized by localized progressive 
degeneration and loss of articular cartilage. This is the most common articular disease affecting to 
more than 50% of population over 65 years of age and also a leading cause of labor inability 
(March and Bachmeier, 1997). OA seems to be a consequence of chondrocyte dysfunction, so 
degradation of extracellular matrix predominates over regeneration. This is accompanied by 
remodelling of subchondral bone, local inflammation of synovia, degeneration of ligaments and 
meniscus and hypertrophy of the joint capsule (Buckwalter and Martin, 2006). When chondrocytes 
are undergoing senescence, they progressively lose the ability to synthesize the extracellular 
matrix and also release proinflammatory cytokines, developing a senescent‐associated secretory 
phenotype (SASP) which aggravates the progression of OA lesions (Watanabe et al., 2017).  
 
OA chondrocytes exhibit a senescent associated phenotype (McCulloch et al., 2017). The 
telomeres of chondrocytes could be involved in the development and progression of OA. 
Accordingly, telomeres from OA chondrocytes are shorter than those from healthy chondrocytes 
and this could precipitate articular senescence (Tamayo et al., 2011). Moreover, the closer the 
articular sample to the OA lesion, the shorter the telomere size (Harbo et al., 2012). This seems to 
be related to advanced senescence and the local severity of the illness. The chondrocyte is not a 
habitual dividing cell. Although chondrocytes from later stage OA may undergo some limited cell 
divisions to try to compensate apoptotic dead cells, the main mechanism of telomere attrition 
should be a consequence of the local oxidative stress associated with a low‐grade chronic 
inflammation characteristic of the disease. In fact, guanines are particularly damaged by oxidative 
stress and telomeres contain G rich sequences and shorten when cells are cultured under 
environments of oxidative stress (Zglinicki, 2002; Yudoh et al., 2005).  
  
Although telomeres from OA chondrocytes clearly seem shortened, the modification of 
telomeres in PBL from OA patients is controversial. Zhai et al. (2006) reported shorter telomeres 
in PBL from patients with hand OA. This was also found in a group of 80 patients with knee OA 
(Poonpet et al., 2017). Nevertheless, Tamayo et al. (2010) did not find significant differences 
between patients with knee OA (n = 34) and controls. The conflicting results may be due to a 
small number of patients. Otherwise, the finding of association between PBL telomeres and OA 
could be an artefact, since other health parameters known to be associated with PBL telomere size, 
like age, hypertension and obesity/body mass index (BMI), could be concomitant in OA patients 
behaving as confunding factors (Zhang et al., 2014; Révész et al., 2014). To accurately confirm the 
association between OA and PBL telomeres, clinically well‐characterized individuals with 
verifiable data of OA severity should be evaluated, using logistic regression analysis to assess the 
possible influence/interference of confunding factors.  
MATERIALS AND METHODS 
Subjects 
In the present study, the association of PBL telomere size with the presence or not of knee OA 
and its associated grade was studied in individuals from a subsample of the Osteoarthritis Initiative 
(OAI) consortium from the USA (n = 310). Subjects were recruited in four centers (Memorial 
Hospital of Rhode Island, The Ohio State University, University of Maryland and Johns Hopkins 
University, and the University of Pittsburgh) between February 2004 and May 2006, with an age 
range of 45–79 years (mean 59.1). The subsample was restricted to Caucasian participants since it 
was initially an element of a research program evaluating the influence of mitocondrial DNA 
(mtDNA) haplogroups in OA, comparing the OAI with a Spanish cohort.  
OA Severity Diagnosis 
In order to maintain objectivity in evaluation of OA severity, individuals were assessed 
through the radiologic knee images, according to the Kellgren–Lawrence (KL) score, ranging from 
0 to 4; 0: no osteophyte or joint space narrowing, that is, without OA (n = 110), 1: questionable 
osteophyte or joint space narrowing (n = 76), 2: small osteophyte(s) or mild joint space narrowing 
(n = 64), 3: moderate osteophyte(s) or joint space narrowing (n = 48), 4: large osteophyte(s) or 
joint space narrowing (n = 12). Prevalent radiographic knee OA at recruitment was defined when 
an individual had a maximum KL grade (max‐KL) ≥2 considering both knees (n = 124). The OAI 
study was approved by the institutional review boards at each OAI clinical site and the 
coordinating center (University of California, San Francisco) and informed consent was obtained 
from the participants.  
Telomere Length Assay 
DNA from PBL was extracted from the blood sample obtained at recruitment in the OAI 
consortium. Coded DNA samples were processed by personnel blinded to the status of the 
subjects. The average telomere amount in PBL was measured with a standard validated 
quantitative PCR (qPCR)‐based assay as described (Tamayo et al., 2010). This method measures 
the average ratio of telomere repeat copy number to a single gene (36B4) copy number (T/S ratio) 
in each sample and may be considered and indirect measure of mean telomere length.  
  
Statistical Analysis 
Data were analyzed using SPSS software (Chicago, Ilinois, USA). Since T/S ratio were not 
normally distributed, as ascertained by the Kolmogorov–Smirnov test, nonparametric Mann–
Whitney U‐test and Spearman's (r) test were performed for homogeneity testing and correlation 
analysis, respectively. Jonckheere–Terpstra test allowed to evaluate the ordered relationship 
between KL grade and T/S ratio. Logistic regression analysis was performed to assess PBL 
telomere size and habitual health parameters as associated risk factors of radiologic knee OA. 
Significance was defined as P < 0.05.  
RESULTS 
PBL telomere length decreased progressively as the max‐KL grade of the knees from the 
individual increased, following a statistically ordered relationship (Jonckheere–Terpstra test, P < 
0.0001) (Table 1). The T/S ratio was significantly shorter in subjects with KL ≥2 in comparison 
with those with KL <2 (Mann–Whitney U‐test, P < 0.0001). Besides radiographic OA, shorter 
PBL telomeres were significant in individuals with hypertension. Moreover, significance was very 
close in subjects with diabetes mellitus, taking into account that there were only 14 in the whole 
population. A negative correlation was also found between the PBL telomere size and age, as well 
as the body mass index (BMI) and waist circumference (Table 2). No differences were found 
between males and females (Mann–Whitney U‐test, P = 0.731).  
Table 1. Statistical Values of Mean Telomere Length (measured as T/S ratio) in Peripheral Blood Leukocytes from 
Subjects without Knee Osteoarthritis (OA), that is, Maximum Radiologic Kellgren–Lawrence (max‐KL) Grade 0 or 1, and 
with Progressive Severity of Knee OA (max‐KL grade from 2 to 4) 
Max‐KL grade N Mean SD Median Min Max 
       
0 110 1.08 0.45 0.94 0.34 2.7 
1 76 0.96 0.27 0.91 0.4 2.05 
2 64 0.81 0.21 0.78 0.38 1.70 
3 48 0.77 0.21 0.75 0.31 1.38 
4 12 0.66 0.19 0.70 0.28 0.96 
       
 
Table 2. Relationship Between PBL Telomere Size and Current Associated Health Factors. Parentheses Indicate Rho 
Spearman Correlation Coefficient 
  
P 
   







BMI (Kg/m2)  Spearman rank correlation <0.001 (−0.259) 
Waist circumference (cm) 
 
0.019 (−0.153) 
   
 
  
Binary regression logistic analysis indicated that age and BMI were risk factors significantly 
associated with radiologic knee OA. Outstandingly, PBL telomere length was discovered to be a 
consistent independent associated‐risk factor contributing to the prevalence of radiologic knee OA, 
independent of age, hypertension, BMI and diabetes (Table 3). Hypertension and diabetes mellitus 
did not reach statistical significance as a risk factor when PBL telomere size was introduced in the 
logistic regression analysis. The magnitude of the associations must be considered within the 
characteristics of the subsample of Caucasian subjects analyzed in the present research and could 
change when studying other populations. 
Table 3. Logistic Regression Analysis of the Association of PBL Telomere Size and Habitual Health Parameters with 
Concurrent Knee Osteoarthritis 
 
Odds ratio 95% Confidence interval P 
    
PBL telomere length (T/S ratio) 0.053 0.02–0.17 <0.001 
Hypertension (Yes/No) 0.982 0.55–1.76 0.982 
Diabetes (Yes/No) 0.918 0.28–3.01 0.918 
Age (years) 1.039 1.01–1.07 0.015 
BMI (Kg/m2)  1.102 1.04–1.17 0.001 
    
 
DISCUSSION 
The association between PBL telomeres and OA concurrence should not be a direct one. 
Chondrocytes and PBL have different lineage origin. Chondrocytes derive from mesenchymal 
stem cells, whereas leukocytes differentiate from hematopoietic stem cells located mainly in the 
bone marrow of adults. Moreover, PBL and chondrocytes exhibit a different turnover rate. Both 
are differentiated, primarily quiescent cell types. But unlike chondrocytes, leukocytes undergo an 
active turnover, variable depending on the different myeloid or lymphoid subpopulations, so the 
mitotic activity of hematopoietic stem cells should be more frequent. Although they exhibit some 
telomerase activity, this is insufficient to prevent telomere shortening associated with DNA 
replication and cell division. The aforementioned fact could explain the differences in telomere 
length in these different cell types, since telomeres from chondrocytes are longer than telomeres 
from PBL from the same subject, even in OA patients (Tamayo et al., 2011). In conclusion, the 
differences in lineage and telomere physiology between PBL and chondrocytes suggest that the 
association between PBL telomere size and risk of presence of knee OA may be indirect.  
 
In spite of their different lineage and turnover, there appears to be a correlation between the 
length of telomeres from leukocytes and from other tissues from the same subject (Okuda et al., 
2002; Wilson et al., 2008). The PBL telomere size was found to be shorter in individuals 
susceptible to several age‐related pathologies, as herein described for knee OA (Ma et al., 2011; 
Zhao et al., 2013; Haycock et al., 2014). Moreover, PBL telomere size is also a recognized marker 
of biological age. Then, PBL telomere size would not be a direct indicator of local disease, but a 
systemic and unspecific marker of biological aging which would not necessarily be correlated with 
chronological age. Systemic accelerated aging may be a consequence of genetic factors, 
environmental causes or both. Subjects with accelerated global biological aging, that is, with 
shorter PBL telomeres, would be more susceptible to age‐related diseases. The development of 
specific age‐associated illness could possibly be determined by the more advanced senescent tissue 
through interaction of telomere biology with other synergistic risk factors (Blackburn et al., 2015).  
  
CONCLUSION 
Based on the present study, a background of accelerated aging could potentiate the effect of 
OA risk factors. Genetic risk factors that influence the incidence and severity of OA include the 
different mtDNA haplogroups, which may modify the production of damaging mitochondrial 
reactive oxygen species (Fernández‐Moreno et al., 2017). Importantly, environmental stressors 
like trauma or interactive environmental–genetic–metabolic influences like obesity or diabetes 
may contribute to OA development and severity, possibly through chronic inflammation. In fact, 
obesity and metabolic syndrome promote biological aging and are associated with shorter PBL 
telomeres (Révész et al., 2014). Increased abdominal adiposity was found to be associated with 
accelerated PBL telomere attrition (Wulaningsih et al., 2016). Shorter PBL telomeres may indicate 
a premature aging condition which enhances chondrocyte senescence. Aged cartilage would be 
less resistant to damaging mechanical, inflammatory and metabolic stressors, thus favoring the 
development and progression of degenerative joint pathology.  
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